Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use. The European-based company is developing next-generation antibody therapeutics for the treatment of cancer. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product.
A symphony of antibodies
If diseases were caused only by a single target they would be relatively easy to treat. Such diseases could be ideally suited for treatment with a single monoclonal antibody able to knock out the disease-causing target.
However, most diseases are complex, and cancer is no exception. Not only do multiple oncogenes cause cancer, but once therapies have been administered, further biological mechanisms may be triggered, often resulting in acquired resistance to the therapy provided, and a poor outcome for the patient.
Such complex diseases require a novel approach with a therapy that must be able to hit multiple targets simultaneously. That's why a mixture of antibodies is required, or as we like to describe it, a ‘symphony of antibodies'. And that's why we're called Symphogen – we're leading the way in the development of antibody mixtures as novel therapies for complex diseases.
Symphogen's lead oncology product, Sym004, is being investigated in two new clinical studies – a Phase 2b study in patients with metastatic colorectal cancer (mCRC) and a Phase 1b study in patients with Non-Small Cell Lung Cancer (NSCLC). Sym004 is an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). Out-licensed worldwide by Symphogen to Merck KGaA in September 2012, Sym004 was the subject of data presentations at the 2013 and 2014 ASCO Annual Meetings in Chicago, IL. At these meetings, Sym004 reported Phase 2 proof-of-concept data in squamous cell carcinoma of the head & neck (SCCHN) and in mCRC that signaled clinical activity and were supportive of the proposed mechanism of action, respectively.
Symphogen has matured its pipeline and has currently brought two product candidates into the clinic. The company's productive technology suite - capable of identifying, selecting and manufacturing optimal antibody mixtures – fuels Symphogen's innovative pipeline. Symphogen has also established the technologies and know-how to manufacture and characterize mAb mixtures as single drug products using standard large-scale biological manufacturing techniques.
In total, the company has raised € 317 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 100 people, most of who are based at Symphogen's facilities in Copenhagen.